Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more
Bavarian Nordic A/S - Asset Resilience Ratio
Bavarian Nordic A/S (BVNKF) has an Asset Resilience Ratio of 5.84% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Bavarian Nordic A/S's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bavarian Nordic A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $884.93 Million | 5.84% |
| Total Liquid Assets | $884.93 Million | 5.84% |
Asset Resilience Insights
- Limited Liquidity: Bavarian Nordic A/S maintains only 5.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bavarian Nordic A/S Industry Peers by Asset Resilience Ratio
Compare Bavarian Nordic A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Bavarian Nordic A/S (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Bavarian Nordic A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.83% | $551.54 Million | $14.41 Billion | +1.11pp |
| 2023-12-31 | 2.72% | $390.25 Million | $14.35 Billion | -15.60pp |
| 2022-12-31 | 18.32% | $2.27 Billion | $12.39 Billion | -7.53pp |
| 2021-12-31 | 25.85% | $3.12 Billion | $12.09 Billion | +10.05pp |
| 2020-12-31 | 15.80% | $1.38 Billion | $8.76 Billion | +13.32pp |
| 2019-12-31 | 2.48% | $174.82 Million | $7.05 Billion | -64.51pp |
| 2018-12-31 | 66.99% | $2.05 Billion | $3.06 Billion | -6.34pp |
| 2017-12-31 | 73.33% | $2.31 Billion | $3.15 Billion | +35.75pp |
| 2016-12-31 | 37.58% | $1.06 Billion | $2.82 Billion | +2.76pp |
| 2015-12-31 | 34.82% | $692.72 Million | $1.99 Billion | +4.02pp |
| 2014-12-31 | 30.80% | $581.35 Million | $1.89 Billion | +18.05pp |
| 2013-12-31 | 12.76% | $185.28 Million | $1.45 Billion | +0.00pp |
| 2012-12-31 | 12.76% | $196.36 Million | $1.54 Billion | -3.02pp |
| 2011-12-31 | 15.78% | $311.92 Million | $1.98 Billion | +9.72pp |
| 2010-12-31 | 6.06% | $88.87 Million | $1.47 Billion | -6.92pp |
| 2007-12-31 | 12.98% | $224.80 Million | $1.73 Billion | -11.26pp |
| 2006-12-31 | 24.24% | $231.32 Million | $954.42 Million | +12.01pp |
| 2005-12-31 | 12.23% | $113.52 Million | $928.56 Million | -- |